secwatch.observer — SEC 8-K summary
======================================

Issuer:     Stoke Therapeutics, Inc. (STOK)
CIK:        0001623526
Form:       8-K
Filed at:   2023-01-09T23:59:59+00:00
Accession:  0001193125-23-004192
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Stoke updates STK-001 Dravet data timelines: 45mg mid-2023, 70mg H2 2023; STK-002 ADOA Phase 1/2 start 2024
--------------------------------------------------------------------------------

- Multiple-dose STK-001 45mg data expected mid-2023; 70mg data expected second half 2023.
- Phase 1/2a for Dravet syndrome to complete in 2023, enabling Phase 3 program in 2024.
- STK-002 for ADOA: UK CTA submission expected H1 2023; Phase 1/2 start planned for 2024.
- Updated corporate presentation posted ahead of J.P. Morgan Healthcare Conference.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1623526/000119312523004192/0001193125-23-004192-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1623526/000119312523004192/d427248d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-004192

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer